HCM 6-K 2026 - Equibles

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

For the Month of June 2026

Commission File Number: 001-37710

HUTCHMED (CHINA) LIMITED

(Translation of registrant’s name into English)

48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ⌧ Form 40-F ◻

HUTCHMED (CHINA) LIMITED

Form 6-K

EXHIBIT INDEX


Exhibit No.		Description

Exhibit 99.1		Announcement relating to blocklisting six monthly return

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	HUTCHMED (CHINA) LIMITED


	By:	/s/ Johnny Cheng
	Name:	Johnny Cheng
	Title:	Chief Financial Officer

Date: June 29, 2026 3

‌Exhibit 99.1

Blocklisting Six Monthly Return

Hong Kong, Shanghai, & Florham Park, NJ — Monday , June 29, 202 6 : HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX: 13) announces the following blocklisting six monthly return:

1.	Name of applicant:<br><br>	HUTCHMED (China) Limited
2.	Name of scheme:<br><br>	(a)Share Option Scheme conditionally adopted by HUTCHMED in 2015 (“2015 HUTCHMED Share Option Scheme”)(b)Share Option Scheme adopted by HUTCHMED in 2026 (“2026 HUTCHMED Share Option Scheme”)

3.	Period of return:<br><br>	From December 29, 2025 to June 28, 2026
4.	Balance under scheme from previous return:<br><br>	(a)2015 HUTCHMED Share Option Scheme: 45,775,868 ordinary shares of US0.1 each(b)2026 HUTCHMED Share Option Scheme: Nil

5.	The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:<br><br>	(a)2015 HUTCHMED Share Option Scheme: Nil(b)2026 HUTCHMED Share Option Scheme: 43,616,756 ordinary shares of US0.1 each

6.	Number of securities issued/allotted under scheme during period:<br><br>	(a)2015 HUTCHMED Share Option Scheme: 7,500(b)2026 HUTCHMED Share Option Scheme: Nil

7.	Balance under scheme not yet issued/allotted at end of the period:<br><br>	(a)2015 HUTCHMED Share Option Scheme: 45,768,368 ordinary shares of US0.1 each(b)2026 HUTCHMED Share Option Scheme: 43,616,756 ordinary shares of US0.1 each

8.	Number and class of securities originally listed and the date of admission:<br><br>	(a)2015 HUTCHMED Share Option Scheme: 23,130,970 ordinary shares of US0.1 each admitted on June 17, 2019 (to replace the Company’s previous block admission scheme following the Company’s share subdivision which took effect on May 30, 2019)(b)2026 HUTCHMED Share Option Scheme: 43,616,756 ordinary shares of US0.1 each admitted on June 11, 2026 following its adoption at the annual general meeting held on May 12, 2026




9.	Total number of securities in issue at the end of the period:<br><br>	872,335,120 ordinary shares of US0.1 each
Name of contact:<br><br>		Weiguo Su / Johnny Cheng

All values are in US Dollars.

Address of contact:<br><br>		Level 18, The Metropolis Tower, 10 Metropolis Drive, Hung Hom, Kowloon, Hong Kong<br><br>
Telephone number of contact:		+852 2121 8200

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

CONTACTS


Investor Enquiries	+852 2121 8200 / [email protected]
Media Enquiries
FTI Consulting –	+44 20 3727 1030 / [email protected]
Ben Atwell / Tim Stamper	+44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)
Brunswick – Zhou Yi	+852 9783 6894 (Mobile) / [email protected]
Panmure Liberum	Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden	+44 20 7886 2500
Cavendish	Joint Broker
Geoff Nash / Nigel Birks	+44 20 7220 0500
Deutsche Numis	Joint Broker
Duncan Monteith / Ramin Naji	+44 20 7545 8000